{"id":"NCT01345682","sponsor":"Boehringer Ingelheim","briefTitle":"LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy","officialTitle":"A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-01-05","primaryCompletion":"2014-03-15","completion":"2016-12-06","firstPosted":"2011-05-02","resultsPosted":"2015-04-14","lastUpdate":"2018-02-15"},"enrollment":483,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Head and Neck Neoplasms","Carcinoma, Squamous Cell"],"interventions":[{"type":"DRUG","name":"Afatinib","otherNames":[]},{"type":"DRUG","name":"Methotrexate","otherNames":[]}],"arms":[{"label":"Afatinib (BIBW 2992)","type":"EXPERIMENTAL"},{"label":"Methotrexate","type":"ACTIVE_COMPARATOR"}],"summary":"This randomised, open-label, phase III study will be performed in patients with R/M head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based therapy. The objectives of the trial are to compare the efficacy and safety of afatinib versus methotrexate","primaryOutcome":{"measure":"Progression-free Survival (PFS) Based on Central Independent Review","timeFrame":"From randomization until disease progression, death or study completion date (06Dec2016); Up to 60 months","effectByArm":[{"arm":"Afatinib (BIBW 2992)","deltaMin":2.63,"sd":null},{"arm":"Methotrexate","deltaMin":1.74,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0257"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":101,"countries":["United States","Argentina","Austria","Belgium","Brazil","Czechia","Denmark","France","Germany","Greece","Israel","Italy","Japan","Mexico","Russia","South Africa","Spain","Sweden","Switzerland"]},"refs":{"pmids":["28961833","27084954","25892145"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":168,"n":320},"commonTop":["Diarrhoea","Rash","Nausea","Mucosal inflammation","Fatigue"]}}